Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (970 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Fluid accumulation within the pericardium. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of thoracic duct. Severe cases can lead to cardiac tamponade.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Effusion, Pericardial; Effusions, Pericardial; Pericardial Effusions; Hemopericardium; Chylopericardium; Chylopericardiums.
Where it fits in the MeSH classification
- Broader topics
- Heart Diseases
- See also
- Cardiac Tamponade
Related concepts
Research landscape
PubMed indexes 9,841 records tagged with the MeSH heading “Pericardial Effusion” (counts retrieved 2026-10-29). 1,290 of them (13.1%) were published from 2020 onward, and the busiest period so far is through 1999 with 4,498 records.
Reviews account for 943 records (9.6%) and meta-analyses for 32. Randomized controlled trials number 80 (0.8%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 4,498 |
| 2000-2009 | 1,798 |
| 2010-2019 | 2,255 |
| 2020 onward | 1,290 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 943 | 9.6% |
| Meta-analyses | 32 | 0.3% |
| Randomized controlled trials | 80 | 0.8% |
Method: PubMed query "Pericardial Effusion"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in cardiovascular medicine
Cardiovascular medicine has an unusually large body of randomized trials, so the type of outcome matters: hard clinical events such as death, heart attack and stroke carry more weight than changes in blood pressure, cholesterol or imaging markers that only predict risk. Observational studies can show associations but are confounded by age, lifestyle and other illness. Check whether a result is about prevention or treatment, the baseline risk of participants, and the absolute rather than only the relative size of any benefit.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection | 2022 | Research article Design not recorded in structured metadata | 39 | cc by PMID 35389890 · DOI · PMC9220849 |
| Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis | 2021 | Research article Design not recorded in structured metadata | 32 | cc by PMID 32914241 · DOI · PMC8055634 |
| Cardiac Magnetic Resonance to Predict Cardiac Mass Malignancy: The CMR Mass Score | 2024 | Research article Design not recorded in structured metadata | 31 | cc by PMID 38502734 · DOI · PMC10949976 |
| Clinical analysis of 255 children with multiple serous effusions | 2026 | Research article Design not recorded in structured metadata | 2 | cc by PMID 41481785 · DOI · PMC12777862 |
Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Shortness of breath, chest pain, and palpitations occur as postacute sequelae of COVID-19, but whether symptoms are associated with echocardiographic abnormalities, cardiac biomarkers, or markers of systemic inflammation remains unknown.
- Closing excerpt
- Investigation into inflammation as a mechanism underlying postacute sequelae of COVID-19 is warranted.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (211 words)
Shortness of breath, chest pain, and palpitations occur as postacute sequelae of COVID-19, but whether symptoms are associated with echocardiographic abnormalities, cardiac biomarkers, or markers of systemic inflammation remains unknown. In a cross-sectional analysis, we assessed symptoms, performed echocardiograms, and measured biomarkers among adults more than 8 weeks after confirmed SARS-CoV-2 infection. We modeled associations between symptoms and baseline characteristics, echocardiographic findings, and biomarkers using logistic regression. We enrolled 102 participants at a median of 7.2 months following COVID-19 onset; 47 individuals reported dyspnea, chest pain, or palpitations. Median age was 52 years, and 41% of participants were women. Female sex, hospitalization, IgG antibody against SARS-CoV-2 receptor binding domain, and C-reactive protein were associated with symptoms. Regarding echocardiographic findings, 4 of 47 participants (9%) with symptoms had pericardial effusions compared with 0 of 55 participants without symptoms; those with effusions had a median of 4 symptoms compared with a median of 1 symptom in those without effusions. There was no strong evidence for a relationship between symptoms and echocardiographic functional parameters or other biomarkers. Among adults more than 8 weeks after SARS-CoV-2 infection, SARS-CoV-2 RBD antibodies, markers of inflammation, and, possibly, pericardial effusions are associated with cardiopulmonary symptoms. Investigation into inflammation as a mechanism underlying postacute sequelae of COVID-19 is warranted.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 35389890 · DOI · PMC9220849
Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis [2]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundPericardial and pleural effusion are common findings in patients with cardiac amyloidosis (CA).
- Closing excerpt
- While pleural effusion was clearly associated with poor RV function in AL, we were not able to detect this association with pericardial effusion.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (254 words)
BackgroundPericardial and pleural effusion are common findings in patients with cardiac amyloidosis (CA). It is not known, whether effusions correlate with right ventricular (RV) function in these patients. Furthermore, data on the prognostic significance of pleural and pericardial effusion in CA is scarce.MethodsPatients with transthyretin (ATTR) and light chain (AL) CA were included in a clinical registry. All patients underwent transthoracic echocardiography at baseline. The presence of pericardial and pleural effusion was determined in every patient. The clinical endpoint was defined as cardiac death or heart failure hospitalization.ResultsIn total, 143 patients were analysed. Of these, 85 patients were diagnosed with ATTR and 58 patients with AL. Twenty-four patients presented with isolated pericardial effusion and 35 with isolated pleural effusion. In 19 patients, both pericardial and pleural effusion were found and in 65 patients no effusion was present at baseline. The presence of pleural effusion correlated well with poor RV function, measured by global RV free-wall strain (p = 0.007) in patients with AL, but not in ATTR. No such correlation could be found for pericardial effusion in either amyloidosis subtype. Patients with AL presenting with pleural effusion had worse outcomes compared to patients with pericardial effusion alone or no effusion at baseline. In the ATTR group, there was no difference in outcomes according to presence and type of effusion.ConclusionMore than 50% of patients with CA presented with pleural and/or pericardial effusions. While pleural effusion was clearly associated with poor RV function in AL, we were not able to detect this association with pericardial effusion.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 32914241 · DOI · PMC8055634
Cardiac Magnetic Resonance to Predict Cardiac Mass Malignancy: The CMR Mass Score [3]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundMultimodality imaging is currently suggested for the noninvasive diagnosis of cardiac masses.
- Closing excerpt
- A CMR mass score of ≥5 predicted a higher risk of all-cause death (PConclusionsA CMR-derived model, including mass morphology and tissue characterization, showed excellent accuracy, superior to echocardiography, in predicting cardiac masses malignancy, with prognostic implications.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (275 words)
BackgroundMultimodality imaging is currently suggested for the noninvasive diagnosis of cardiac masses. The identification of cardiac masses' malignant nature is essential to guide proper treatment. We aimed to develop a cardiac magnetic resonance (CMR)-derived model including mass localization, morphology, and tissue characterization to predict malignancy (with histology as gold standard), to compare its accuracy versus the diagnostic echocardiographic mass score, and to evaluate its prognostic ability.MethodsObservational cohort study of 167 consecutive patients undergoing comprehensive echocardiogram and CMR within 1-month time interval for suspected cardiac mass. A definitive diagnosis was achieved by histological examination or, in the case of cardiac thrombi, by histology or radiological resolution after adequate anticoagulation treatment. Logistic regression was performed to assess CMR-derived independent predictors of malignancy, which were included in a predictive model to derive the CMR mass score. Kaplan-Meier curves and Cox regression were used to investigate the prognostic ability of predictors.ResultsIn CMR, mass morphological features (non-left localization, sessile, polylobate, inhomogeneity, infiltration, and pericardial effusion) and mass tissue characterization features (first-pass perfusion and heterogeneity enhancement) were independent predictors of malignancy. The CMR mass score (range, 0-8 and cutoff, ≥5), including sessile appearance, polylobate shape, infiltration, pericardial effusion, first-pass contrast perfusion, and heterogeneity enhancement, showed excellent accuracy in predicting malignancy (areas under the curve, 0.976 [95% CI, 0.96-0.99]), significantly higher than diagnostic echocardiographic mass score (areas under the curve, 0.932; P=0.040). The agreement between the diagnostic echocardiographic mass and CMR mass scores was good (κ=0.66). A CMR mass score of ≥5 predicted a higher risk of all-cause death (PConclusionsA CMR-derived model, including mass morphology and tissue characterization, showed excellent accuracy, superior to echocardiography, in predicting cardiac masses malignancy, with prognostic implications.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38502734 · DOI · PMC10949976
Clinical analysis of 255 children with multiple serous effusions [4]
Abstract reading summary — source excerpts
- Opening excerpt
- BackgroundThis study aimed to analyze the etiological spectrum, clinical features, and pathological correlates of multiple serous effusions in pediatric patients to inform clinical decision-making.
- Closing excerpt
- The number of affected cavities may serve as an indicator of disease severity.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (230 words)
BackgroundThis study aimed to analyze the etiological spectrum, clinical features, and pathological correlates of multiple serous effusions in pediatric patients to inform clinical decision-making.Materials and methodsA retrospective study was conducted on 255 children diagnosed with multiple serous effusions at the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University between January 1, 2014, and July 1, 2024.ResultsThe most common identified causes were pneumonia (n = 80, 31.37%), and trauma (n = 28, 10.98%). Etiologies demonstrated age and sex-specific patterns. Pneumonia predominated in preschool/school-aged children, and trauma was more common among preschool/school-aged boys. Tumors mainly affected school-aged/adolescent males, while connective tissue diseases (primarily systemic lupus erythematosus) predominated in adolescent females. Pleural effusion was the most common manifestation (n = 243, 95.3%), followed by peritoneal (n = 187, 73.3%) and pericardial effusions (n = 136, 53.3%). The nature and distribution of effusions correlated with the underlying disease. Pneumonia/tumor cases exhibited higher susceptibility to pleural and pericardial effusions, predominantly exudative. Connective tissue disease cases frequently demonstrated involvement of all three serous cavities, predominantly exudative. Cardiac insufficiency cases typically presented with transudative effusions. The triple serous cavity effusion group exhibited significantly lower hemoglobin, serum albumin, calcium, and IgM levels (p p ConclusionThe etiology of pediatric multiple serous effusions is diverse and closely linked to patient age and effusion location. The number of affected cavities may serve as an indicator of disease severity.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41481785 · DOI · PMC12777862
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS) [5]
- Research article Management of pericardial effusion [6]
- Research article CT and MR imaging of pericardial disease [7]
- Research article Cardiac tamponade and pericardial effusion: respiratory variation in transvalvular flow velocities studied by Doppler echocardiography [8]
- Research article Treatment of malignant pericardial effusion [9]
- Research article Does this patient with a pericardial effusion have cardiac tamponade? [10]
References
- Durstenfeld MS, Peluso MJ, Kelly JD, Win S, Swaminathan S, Li D, et al.. Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. . 2022. PMID 35389890 · DOI · PMC9220849
- Binder C, Duca F, Binder T, Rettl R, Dachs TM, Seirer B, et al.. Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis. . 2021. PMID 32914241 · DOI · PMC8055634
- Paolisso P, Bergamaschi L, Angeli F, Belmonte M, Foà A, Canton L, et al.. Cardiac Magnetic Resonance to Predict Cardiac Mass Malignancy: The CMR Mass Score. . 2024. PMID 38502734 · DOI · PMC10949976
- Jin W, Lu L, Gao Q, Lou T, Hu W, Chen Y, et al.. Clinical analysis of 255 children with multiple serous effusions. . 2026. PMID 41481785 · DOI · PMC12777862
- Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al.. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015. PMID 26320112 · DOI · PMC7539677
- Imazio M, Adler Y. Management of pericardial effusion. Eur Heart J. 2013. PMID 23125278 · DOI
- Wang ZJ, Reddy GP, Gotway MB, Yeh BM, Hetts SW, Higgins CB. CT and MR imaging of pericardial disease. Radiographics. 2003. PMID 14557510 · DOI
- Appleton CP, Hatle LK, Popp RL. Cardiac tamponade and pericardial effusion: respiratory variation in transvalvular flow velocities studied by Doppler echocardiography. J Am Coll Cardiol. 1988. PMID 3281990 · DOI
- Vaitkus PT, Herrmann HC, LeWinter MM. Treatment of malignant pericardial effusion. JAMA. 1994. PMID 8007081 · DOI
- Roy CL, Minor MA, Brookhart MA, Choudhry NK. Does this patient with a pericardial effusion have cardiac tamponade?. JAMA. 2007. PMID 17456823 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.